| Name | Title | Contact Details |
|---|
Horizon Blue Cross Blue Shield of New Jersey, the only licensed Blue Cross and Blue Shield plan in New Jersey, provides health insurance coverage to more than 3.6 million people throughout all of North, Central, and South Jersey. Horizon Blue Cross Blue Shield of New Jersey is best known for our managed care and traditional indemnity plans for individuals and employers — the cornerstone of our health care business. Horizon BCBSNJ traces its history back to 1932 when Associated Hospitals of Essex County, Inc. was formed as a multi-hospital prepayment plan. The company later became the nation`s first Blue Cross Plan. Horizon Blue Cross Blue Shield of New Jersey, is a not-for-profit, health service corporation. A 15-member Board of Directors governs the company for its members. There are no shareholders.
KishHealth System is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. KishHealth System is based in Dekalb, IL. You can find more information on KishHealth System at www.kishhealth.org
TeamHealth Medical Call Center is a Knoxville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genzyme Corporation is a fully owned subsidiary of Sanofi. Before its acquisition in 2011, Genzyme was an American biotechnology company based in Cambridge, Massachusetts. In 2010, Genzyme was the world`s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 40 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenues with more than 25 products in the market. In 2006 and 2007 Genzyme was named one of Fortune Magazine`s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America`s leading innovators.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic